Naslov
Osteoporosis and renal osteodystrophy - osteoprotegerin indicates difference in bone turnover

Autori
Kusec, Vesna ; Bilic, Karmen ; Jelcic, Jozo ; Giljevic, Zlatko ; Smalcelj, Ruzica ; Kastelan, Darko ; Perkovic, Zdravko ; Korsic, Mirko ; Szekeres, Thomas

Izvornik
Bone (New York, N.Y.) (8756-3282) 33 (2003), 5; S25-S26

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kongresno priopcenje, znanstveni

Ključne riječi
osteoprotegerin; postmenopausal osteoporosis; renal osteodystrophy; bone turnover

Sažetak
Osteoprotegerin is an important factor in the regulation of bone turnover. The function of this soluble receptor for osteoprotegerin ligand/osteoclast differentiation factor is blocking its binding and activation of ODAR/RANK (osteoclast differentiation and activation receptor) on osteoclast surface and arresting terminal phase of its differentiation, reduction of activation of mature osteoclasts and stimulation of its apoptosis. The aim of this study was measurement of osteoprotegerin in the postmenopausal osteoporosis and renal osteodystrophy after kidney transplantation, metabolic disorders of different bone turnover intensity. This study comprised 42 women with postmenopausal osteoporosis and 40 kidney transplant recipients. The following biochemical parameters were determined by commercial ELISA kits: osteoprotegerin (Osteoprotegerin, Biomedica), bone alkaline phosphatase (Alkphase B, Metra Biosystems) and telopeptide (Crosslaps Serum, Osteometer). In kidney transplant recipients bone alkaline phosphatase (p<0.01) and telopeptide (p<0.001) were significantly higher, osteoprotegerin significantly lower (p<0.04) than in women with postmenopausal osteoporosis. Statistically significant and positive correlation )p<0.0009) existed between bone alkaline phosphatase and telopeptide for the entire patient group and only in kidney transplant recipients. These results indicate that in conditions characterised by high bone turnover osteoprotegerin secretion is significantly less than in conditions with moderate bone turnover rate. Correspondence of osteoprotegerin with standard bone markers could not be demonstrated in this patient group, probably due to high variance and sample size. Evaluation of clinical usefulness of osteoprotegerin measurement remains to be further investigated.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA